DUBLIN--(BUSINESS WIRE)--The "APAC's Bioprocessing Facilities Report 2020" report has been added to ResearchAndMarkets.com's offering.
The biologics industry is evolving at an unprecedented rate by demanding for new and improved technologies to reduce cost and increase efficiency. The world is seeing an increase in biopharma facilities, especially in Asia to meet the growing demands of biologic drugs. Yet, the number one factor reported to cause capacity constraints at bioprocessing facilities in the near future is facility constraints.
Hence, the publisher has put together a comprehensive report on 65+ bioprocessing facilities in the past ten years that have been constructed in the Asia- Pacific region including countries such as China, India, Korea, Japan, SEA, Australia. This report will provide detailed analysis from their manufacturing capabilities, Process Technologies to key details on their Facility Construction Design.
The "APAC's Bioprocessing Facilities 2020" report covers bioprocessing facilities in China, Japan, Korea, Taiwan, SEA, India and Australia. The 150 page report covers comprehensive information on parameters of manufacturing capabilities such as facility size, capacity, production technologies, type of biologics manufactured and much more.
In addition, the directory features some of the checklists based on DesignFlex30 and highlights examples of companies that have constructed their facilities in a flexible manner catering to the fast-changing needs of the industry. Moreover, in-depth studies on the bioprocessing landscape have supplemented the report with a swot analysis and future forecasts. It provides readers a closer look into the facilities of Chugai, Hanmi, Daiichi Sankyo, Biocon,( India & SEA) Beigene, Amgen (Singapore), GSK (Singapore), Biocon, AlphaMab, BeiGene, Innovent Biologics, Tot Biopharma.
Key Topics Covered:
Section 1
- Preface
- Report Scope & Data Coverage
- Research Methodology
Section 2: Bioprocessing Facilities in Greater China
- Henlius Pharma
- Innovent Biologics
- Pfizer
- Tonhua Dongbao
- AlphaMab
- Akeso Pharmaceuticals
- Hanmi Pharma
- Sinovac
- BeiGene
- Junshi Biosciences
- Tot Biopharma
- Hualan Biological Engineering
Section 3: Bioprocessing Facilities In Korea And Japan
- Samsung Bioepis
- Astellas
- Celltrion
- Chugai
- Hanmi Pharma
- Kyowa Hakko Kirin
- Aprogen Biologiccs
- Daiichi Sankyo
Section 4: Bioprocessing Facilities In India And Australia
- Aurobindo
- CSL Bering
- Serum Institute of India
- CSIRO
- Enzene Biosciences
- Stelis Biopharma
Section 5: Bioprocessing Facilities In South-East-Asia
- Abbvie
- GSK
- AJ Biologics
- Amgen
- Novartis Thailand
- Baxter
- Takeda
- Siam Biosciences
Section 6: Region-Wise Data & Analysis Of Manufacturing Facility {Regions Covered: China, Taiwan, Japan& Korea, India, Australia & Sea}
- Products Manufactured: Vaccines - Cell Therapy - Recombinant Proteins & Mabs - Others
- Technologies Housed and Bioprocessing Processes
- Plant Capacity
- Projects In Pipeline
- Biomanufacturing Investment
- Regulatory Approvals
- Facility Size, Design
- Financial Insights
- Pestel Analysis
Companies Mentioned
- Henlius Pharma
- Innovent Biologics
- Pfizer
- Tonhua Dongbao
- AlphaMab
- Akeso Pharmaceuticals
- Hanmi Pharma
- Sinovac
- BeiGene
- Junshi Biosciences
- Tot Biopharma
- Hualan Biological Engineering
- Samsung Bioepis
- Astellas
- Celltrion
- Chugai
- Hanmi Pharma
- Kyowa Hakko Kirin
- Aprogen Biologiccs
- Daiichi Sankyo
- Aurobindo
- CSL Bering
- Serum Institute of India
- CSIRO
- Enzene Biosciences
- Stelis Biopharma
- Abbvie
- GSK
- AJ Biologics
- Amgen
- Novartis Thailand
- Baxter
- Takeda
- Siam Biosciences
For more information about this report visit https://www.researchandmarkets.com/r/pm5jc3
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
